A rheumatologist prescribes celecoxib for osteoarthritis in a 70-year-old patient. The patient asks why it was chosen over ibuprofen. At the molecular level, what SPECIFICALLY makes COX-2 selective inhibitors structurally feasible?

• A COX-2 is only expressed in the GI mucosa and platelet-forming cells, allowing targeted selectivity with no cardiovascular risk
• B COX-2 inhibitors bind the peroxidase active site rather than the cyclooxygenase channel, making them automatically selective
• C COX-2 inhibitors are selectively distributed to inflamed tissue due to the enhanced permeability effect and never reach COX-1 expressing tissues
• D COX-2 has a larger, more accessible hydrophobic channel than COX-1, with a valine at position 523 (instead of isoleucine in COX-1), creating a side pocket accessible only by bulkier inhibitors ✓

Explanation

COX-1 and COX-2 share nearly identical cyclooxygenase active sites, but COX-2 has a valine residue at position 523 instead of the isoleucine found in COX-1. Isoleucine's larger side chain blocks access to a hydrophobic side pocket adjacent to the main binding channel. Valine's smaller side chain in COX-2 creates an accessible secondary pocket (the 'COX-2 side pocket'). Selective COX-2 inhibitors (coxibs) have a sulfonyl/sulfonamide group that fits into this additional COX-2 pocket, conferring selectivity. Importantly, COX-2 selective inhibitors spare COX-1-mediated thromboxane A2 production in platelets (pro-aggregatory) while inhibiting endothelial COX-2-derived prostacyclin (anti-aggregatory), explaining the prothrombotic cardiovascular risk.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.